Authors

Joshua M. Bauml, MD, Rena Rowan Breast Center

Joshua M. Bauml, MD, University of Pennsylvania

Joshua M. Lang, MD

Latest:

Need for Dynamic, Predictive Biomarkers Remains Pressing

Despite advances, the majority of patients receiving targeted therapies do not experience radiographic responses, and nearly all patients who initially benefit develop resistance in less than two years.

Joshua M. Lawrenz, MD

Latest:

Dr. Lawrenz on Patient Feedback of Preoperative 5-Fraction RT Sarcoma Study

Joshua M. Lawrenz, MD, discusses patient feedback of a study on preoperative 5-fraction radiation therapy for soft tissue sarcoma with immediate resection.

Joshua Meeks, MD, PhD

Latest:

Dr. Meeks Discusses Smoking Status in Bladder Cancer

Joshua Meeks, MD, PhD, assistant professor of urology, biochemistry, and molecular genetics, Northwestern University Feinberg School of Medicine, section chief of robotic surgery, Jesse Brown VA Medical Center, discusses the role of smoking status in the diagnosis of bladder cancer.

Joshua P. Sasine, MD

Latest:

Dr. Sasine on CAR T-Cell Therapy in Ovarian Cancer

Joshua P. Sasine, MD, medical director, Chimeric Antigen Receptor T-Cell Program, David Geffen School of Medicine, University of California, Los Angeles, discusses chimeric antigen receptor (CAR) T- cell therapy in ovarian cancer.

Joshua P. Sasine, MD, PhD

Latest:

Dr Sasine on the Potential Use of Cilta-Cel in Earlier Lines for Multiple Myeloma

Joshua P. Sasine, MD, PhD, discusses the potential role of cilta-cel in earlier lines of therapy for patients with multiple myeloma.

Joshua Richter, MD

Joshua Richter, MD, is Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology.

Latest:

Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD

Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.

Joshua Roth, PhD

Latest:

The Design Behind the Development of a Novel-Risk Prediction Model in Lung Cancer Screening

Joshua Roth, PhD, assistant member, Fred Hutchinson Cancer Research Center, discusses the design of a novel risk-prediction algorithm in the context of screening patients for lung cancer.

Joshua Sabari, MD

Latest:

HER2 Alteration Testing In Advanced and Metastatic NSCLC

Panelists discuss how comprehensive next-generation sequencing testing is essential for identifying HER2 mutations in patients with stage IV non–small cell lung cancer, distinguishing between HER2 mutations (detected by DNA sequencing) and HER2 overexpression/amplification (detected by immunohistochemistry).

Joyce A. O

Joyce A. O'Shaughnessy, MD, US Oncology

Joyce A. O'Shaughnessy

Latest:

Dr. O'Shaughnessy on Key Results From the EMERALD Trial in HR+/HER2- Breast Cancer

Joyce A. O’Shaughnessy, MD, discusses key results from the phase 3 EMERALD trial of elacestrant, and the potential effects of the agent’s approval on the use of oral selective estrogen receptor degraders for hormone receptor–positive, HER2-negative breast cancer.

Joyce A. O'Shaughnessy, MD

Joyce A. O'Shaughnessy, MD, is co-chair of Breast Cancer Research and chair of Breast Cancer Prevention Research at Baylor Charles A. Sammons Cancer Center

Latest:

Dr O’Shaughnessy on Highly Anticipated Breast Cancer Data to Watch at ESMO 2025

Joyce A. O’Shaughnessy, MD, highlights the breast cancer data being presented at ESMO 2025 that have the greatest potential to shape clinical practice.

Joyce A. OShaughnessy, MD, Balor University Medical Center

Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center

Latest:

Decision Factors for SubQ Therapy and Unmet Needs

Joyce A. OShaughnessy, MD, Baylor-Sammons Cancer Center

Joyce A. OShaughnessy, MD, Baylor University Medical Center

Joyce A. O'Shaughnessy, MD, US Oncology

Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center